Literature DB >> 26890105

Hemorheological parameters better classify metabolic syndrome than novel cardiovascular risk factors and peripheral vascular disease marker.

Prajwal Gyawali1, Ross S Richards1, Paul Tinley2, Ezekiel Uba Nwose3, Phillip T Bwititi4.   

Abstract

The present study compares the association of Metabolic Syndrome (MetS) with hemorheological parameters, oxidative stress, inflammation and peripheral arterial disease markers. 100 participants were recruited and participants were divided into three groups on the basis of absence or presence of MetS and its components. Odds ratio for correctly predicting MetS was highest for erythrocyte aggregation followed by erythrocyte deformability. ROC curve analysis demonstrated that all the hemorheological components significantly classified MetS participants. Area Under Curve was higher for the hemorheological parameters (erythrocyte aggregation and erythrocyte deformability) than for the oxidative stress, inflammation and peripheral arterial disease markers. The possibilities of the hemorheological components to be identified as better cardiovascular risk markers due to their strong association with MetS cannot be precluded from the present findings.

Entities:  

Keywords:  Hemorheology; ROC curve; inflammation; oxidative stress

Mesh:

Substances:

Year:  2016        PMID: 26890105     DOI: 10.3233/CH-152033

Source DB:  PubMed          Journal:  Clin Hemorheol Microcirc        ISSN: 1386-0291            Impact factor:   2.375


  2 in total

Review 1.  Potential Diagnostic Hemorheological Indexes for Chronic Kidney Disease in Patients With Type 2 Diabetes.

Authors:  Hoyoon Lee; Wonwhi Na; Sang Bae Lee; Chul Woo Ahn; Jun Sung Moon; Kyu Chang Won; Sehyun Shin
Journal:  Front Physiol       Date:  2019-08-20       Impact factor: 4.566

Review 2.  The Effect of Ginkgo Biloba Dropping Pills on Hemorheology and Blood Lipid: A Systematic Review of Randomized Trials.

Authors:  Hong Chen; Cihang Zhou; Mingwei Yu; Shuo Feng; Yunfei Ma; Zhengrong Liu; Jiahui Zhang; Tongjing Ding; Bo Li; Xiaomin Wang
Journal:  Evid Based Complement Alternat Med       Date:  2019-06-26       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.